Understanding the Regulatory and Ethical Challenges of Pediatric Trials in India

Introduction

Pediatric clinical trials are essential for ensuring the safety and efficacy of medical treatments in children, a population with distinct physiological and developmental needs. However, conducting such trials presents unique scientific, ethical, and regulatory challenges worldwide — and particularly in India, where infrastructural disparities, regulatory evolution, and socio-cultural complexities create additional hurdles.

India’s large pediatric population — over 40% of its 1.4 billion citizens — represents a critical demographic for clinical research. Yet, less than 10% of all registered clinical trials in India involve pediatric participants. The Indian regulatory system has responded to this gap through initiatives embedded in the New Drugs and Clinical Trials Rules (NDCTR) 2019, along with ethical frameworks from the Indian Council of Medical Research (ICMR) and international guidance from ICH and WHO.

This article delves into the current landscape of pediatric clinical trials in India, highlighting the challenges, evolving regulations, and best practices for conducting ethically sound and scientifically robust studies involving children.

Background / Regulatory Framework

CDSCO and NDCTR 2019 Provisions

The Central Drugs Standard Control Organization (CDSCO) regulates pediatric trials under the NDCTR 2019. These rules replaced Schedule Y and laid out clearer requirements for vulnerable populations, including minors. Key highlights include:

• Mandatory Ethics Committee approval with pediatric expertise
• Need for age-specific assent and informed consent
• Provision for compensation in case of trial-related injury or death
• Special scrutiny for Phase I trials involving children

ICMR Ethical Guidelines (2017)

ICMR’s guidelines emphasize protection of child participants while promoting research that addresses their specific health needs. Key elements include:

• Assent from children aged 7–18 years, in age-appropriate language
• Parental or legal guardian consent for all participants below 18
• Risk-benefit analysis favoring minimal risk unless direct benefit is expected
• Mandatory psychological support for trials involving serious conditions

International Benchmarks

Indian regulators also refer to guidance from:

• ICH E11 (Clinical Investigation of Medicinal Products in the Pediatric Population)
• WHO’s “Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Pediatric Population”
• EMA’s Pediatric Regulation (EC) No 1901/2006

Core Clinical Trial Insights

1. Trial Design and Dosing Challenges

Children are not simply “small adults.” Their metabolic rate, drug absorption, and immune responses differ by age group. Pediatric trials in India must account for these variations through:

• Age-stratified cohorts (neonates, infants, children, adolescents)
• Use of pharmacometric modeling and simulation for dosing predictions
• Scaled pediatric formulations (e.g., oral suspensions, mini-tablets)
• Bridging studies where adult data are available

2. Ethical Consent and Assent Complexities

India’s diverse linguistic and educational landscape complicates the informed consent process. Key considerations include:

• Translation of consent and assent forms into regional languages
• Use of visual aids for illiterate or semi-literate parents
• Clarifying trial-related risks and benefits to both child and guardian
• Documenting separate assent (ages 7–18) and guardian consent

Ethics Committees must have pediatric experts to review and approve such documents.

3. Site Preparedness and Infrastructure

Many Indian trial sites lack pediatric-specific infrastructure such as:

• Child-friendly examination rooms and equipment
• Trained pediatric nurses and counselors
• On-site access to pediatric emergency services

Only tertiary care hospitals and select academic institutions like AIIMS or PGIMER are fully equipped for complex pediatric trials.

4. Safety Monitoring and Pharmacovigilance

Children may not verbalize adverse events clearly, requiring vigilant AE monitoring through:

• Caregiver reports and behavioral assessments
• Regular check-ins post-dose
• Use of age-appropriate toxicity grading scales

The Pharmacovigilance Program of India (PvPI) is developing special modules for pediatric signal detection and post-trial follow-up.

5. Recruitment Challenges and Cultural Sensitivities

Recruiting children into trials is fraught with emotional and cultural barriers. In India, additional issues include:

• Parental mistrust of pharmaceutical trials
• Lack of awareness about rare diseases and trial benefits
• Gender bias (girls less likely to be enrolled in studies)

Community-based outreach and inclusion of pediatricians in trial education efforts are essential.

6. Compensation and Risk-Based Classification

As per NDCTR 2019, if a child suffers trial-related harm, compensation must be provided. Risk categorization also plays a role in ethics review:

• Minimal risk: Daily life activities (e.g., minor blood draw)
• Minor increase over minimal risk: Non-invasive observational studies
• More than minimal risk: Allowed only if direct benefit exists

Best Practices & Preventive Measures

• Design protocols using input from pediatricians and developmental psychologists
• Implement patient and parent education programs with NGOs and advocacy groups
• Use digital tools for monitoring behavior and vitals in outpatient pediatric trials
• Ensure child protection policies at all trial sites
• Mandate trial insurance that explicitly covers pediatric participants

Scientific & Regulatory Evidence

• NDCTR 2019: New Drugs and Clinical Trial Rules
• ICMR National Ethical Guidelines (2017)
• Schedule Y of Drugs and Cosmetics Act (Historical Reference)
• ICH E11 Guidance
• PvPI Safety Reports – Pediatric Submissions
• WHO Pediatric Trial Ethics (2011)

Special Considerations

1. Rare Disease Trials in Pediatric Populations

India has no formal orphan drug regulation yet, making pediatric rare disease trials a gray area. Government programs like Nidan Kendras and national registries are helping generate data for this population.

2. Pediatric Vaccine Trials

COVID-19 significantly advanced India’s pediatric trial capacity through vaccine studies conducted by Bharat Biotech, Serum Institute, and others. Regulatory agencies now have more experience reviewing pediatric vaccine protocols.

3. Use of Digital Technologies

eConsent tools, wearable devices, and mobile health apps are increasingly being piloted for adolescent clinical trials in urban India, especially for diabetes and mental health interventions.

When Sponsors Should Seek Regulatory Advice

• When developing new pediatric formulations or delivery routes
• For first-in-human studies in Indian children
• If international data need bridging with Indian pediatric populations
• For trials involving neonates or life-threatening conditions
• When seeking fast-track review or public sector co-funding

FAQs

1. What is the minimum age for giving assent in India?

Children aged 7 years and above must provide verbal or written assent, depending on maturity and study type.

2. Can Phase I trials be done in Indian children?

Only if the drug is intended exclusively for pediatric use and there is robust preclinical and adult data. CDSCO reviews such proposals stringently.

3. Are Indian pediatric trials recognized internationally?

If they follow ICH-GCP and are registered in CTRI, they are generally acceptable for global submission, especially if sites are accredited.

4. What is the role of Ethics Committees in pediatric trials?

ECs must include pediatricians and child rights experts. They review consent forms, monitor adverse events, and conduct interim reviews.

5. Can children be enrolled in AYUSH clinical trials?

Yes, provided the formulations are age-appropriate and EC approvals are in place. CCRAS has conducted several such studies.

Conclusion

Pediatric clinical trials in India are gradually evolving to meet the complex demands of child-specific drug development and public health needs. While regulatory clarity and infrastructure improvements are ongoing, a combination of robust ethics, targeted site preparation, and community engagement will determine the success and ethical integrity of these vital studies.